HC Wainwright & Co. Reiterates Buy on LAVA Therapeutics, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Arthur He has reiterated a Buy rating on LAVA Therapeutics (NASDAQ:LVTX) and maintained a $6 price target for the company's stock.
November 17, 2023 | 11:23 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Arthur He reaffirmed a Buy rating on LAVA Therapeutics with a $6 price target, indicating a positive outlook for the stock.
The reiteration of a Buy rating and the maintenance of a price target by a reputable analyst typically instill confidence in investors and can lead to a positive short term impact on the stock price. Given that the price target is maintained and not lowered, it suggests the analyst's continued belief in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100